Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies

The blockade of immune regulatory checkpoints is emerging as a powerful anticancer strategy. We recently reported long-term results from the first-in-human clinical trial of anti-PD1 antibody-based immunotherapy, demonstrating durable tumor control off-therapy in subjects affected by colorectal and...

Descripción completa

Detalles Bibliográficos
Autor principal: Lipson, Evan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654592/
https://www.ncbi.nlm.nih.gov/pubmed/23734322
http://dx.doi.org/10.4161/onci.23661
_version_ 1782269587694288896
author Lipson, Evan J.
author_facet Lipson, Evan J.
author_sort Lipson, Evan J.
collection PubMed
description The blockade of immune regulatory checkpoints is emerging as a powerful anticancer strategy. We recently reported long-term results from the first-in-human clinical trial of anti-PD1 antibody-based immunotherapy, demonstrating durable tumor control off-therapy in subjects affected by colorectal and kidney cancer, as well as successful re-induction therapy in a melanoma patient.
format Online
Article
Text
id pubmed-3654592
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36545922013-06-03 Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies Lipson, Evan J. Oncoimmunology Author's View The blockade of immune regulatory checkpoints is emerging as a powerful anticancer strategy. We recently reported long-term results from the first-in-human clinical trial of anti-PD1 antibody-based immunotherapy, demonstrating durable tumor control off-therapy in subjects affected by colorectal and kidney cancer, as well as successful re-induction therapy in a melanoma patient. Landes Bioscience 2013-04-01 2013-04-01 /pmc/articles/PMC3654592/ /pubmed/23734322 http://dx.doi.org/10.4161/onci.23661 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Lipson, Evan J.
Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies
title Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies
title_full Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies
title_fullStr Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies
title_full_unstemmed Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies
title_short Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies
title_sort re-orienting the immune system: durable tumor regression and successful re-induction therapy using anti-pd1 antibodies
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654592/
https://www.ncbi.nlm.nih.gov/pubmed/23734322
http://dx.doi.org/10.4161/onci.23661
work_keys_str_mv AT lipsonevanj reorientingtheimmunesystemdurabletumorregressionandsuccessfulreinductiontherapyusingantipd1antibodies

Ejemplares similares